{
  "id": 14428631,
  "title": "RBC Capital reiterates Axsome Therapeutics stock rating at Outperform",
  "url": "https://urgent.news/2026/10/14/rbc-capital-reiterates-axsome-therapeutics-stock-rating-at-outperform",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-14T10:46:56.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/rbc-capital-reiterates-axsome-therapeutics-stock-rating-at-outperform-93CH-4948702"
  },
  "original_language": "en",
  "account": "RBC Capital has maintained its \"Outperform\" rating on Axsome Therapeutics (NASDAQ:AXSM) with a $295.00 price target. The stock has fallen about 28% over the past month, compared to a 6% decline in the XBI index, due to lower-than-anticipated prescription trends. Currently trading at $156.32, the stock is down 14% year-to-date. However, RBC Capital's RSI indicates the stock is in oversold territory. The firm notes Axsome now trades roughly 15% lower than before the Alzheimer's disease agitation approval, deeming the stock fundamentally undervalued. InvestingPro analysis supports this view, with a Pro Research Report available for further insight. Recent prescription trends are attributed to seasonal effects and sampling dynamics, not a lack of product launch impact. RBC Capital sees a $2.3 billion opportunity in Alzheimer's disease agitation by 2035. Shares are currently trading at around $155. Despite lower expectations for the quarter, RBC Capital believes such concerns are manageable. Axsome Therapeutics reported $218.4 million in revenue for the second quarter of 2026, surpassing H.C. Wainwright's forecast of $211.1 million. The company also recorded a net loss of $0.99 per share, matching expectations. Mizuho recently raised its price target to $316, citing optimism around Auvelity's launch and commercial execution. H.C. Wainwright echoed this sentiment with a \"Buy\" rating and $290 price target, emphasizing the impact of agitation symptoms on patients and families. Truist Securities also initiated coverage with a \"Buy\" rating and $285 target, signaling strong growth potential. Wells Fargo included Axsome in its list of overweight tactical ideas, predicting accelerated growth due to Auvelity prescriptions. These updates highlight increased interest and confidence in Axsome's commercial strategies and product prospects. This report was AI-generated and reviewed by an editor.",
  "summary": null,
  "key_points": [
    "RBC Capital maintains Outperform rating on Axsome Therapeutics with $295 price target.",
    "Stock down 28% month-to-date, 14% YTD, trading 15% below pre-Alzheimer's approval price.",
    "RBC Capital sees $2.3B opportunity in Alzheimer's disease agitation by 2035."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}